Mylan nebivolol “approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Mylan's beta blocker nebivolol is "approvable" May 31 for treatment of hypertension. "Final approval of nebivolol is contingent upon successfully satisfying additional FDA requirements regarding certain aspects of the preclinical data and finalization of the labeling," Mylan said. The company is conducting a preclinical study, expected to be complete by year end, which it believes will answer FDA's questions. The agency extended nebivolol's initial user fee deadline of Feb. 28 by 90 days following the sponsor's submission of an "additional presentation of already submitted data" (1Pharmaceutical Approvals Monthly March 2005, p. 8). Mylan announced during a June 14 conference call that it is also targeting a congestive heart failure claim for nebivolol and expects to have a licensing partner by fall...
You may also be interested in...
Mylan would launch nebivolol with a hypertension indication soon after approval if it appears FDA consent for a supplemental indication in congestive heart failure would be far off, the company said
Mylan nebivolol user fee date extended to May 31 after submission of additional analyses of already submitted data, firm says. Mylan had planned to use proposed merger partner King’s sales force for the beta blocker before the deal collapsed in eleventh hour. Mylan may seek another partner, but licensor J&J has last call
Australia will begin its coronavirus vaccination program with Comirnaty. The Oxford University/AstraZeneca vaccine is expected to be the next to receive approval.